652 related articles for article (PubMed ID: 30905548)
21. Current and emerging immunotherapeutic approaches for biliary tract cancers.
Yuan ZG; Zeng TM; Tao CJ
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
[TBL] [Abstract][Full Text] [Related]
22. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P
Cells; 2020 Mar; 9(3):. PubMed ID: 32168869
[TBL] [Abstract][Full Text] [Related]
23. Medical treatment for cholangiocarcinoma.
Adeva J; Sangro B; Salati M; Edeline J; La Casta A; Bittoni A; Berardi R; Bruix J; Valle JW
Liver Int; 2019 May; 39 Suppl 1():123-142. PubMed ID: 30892822
[TBL] [Abstract][Full Text] [Related]
24. Current and emerging therapies for advanced biliary tract cancers.
Kam AE; Masood A; Shroff RT
Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):956-969. PubMed ID: 34626563
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies.
Alsina M; Moehler M; Lorenzen S
Oncol Res Treat; 2018; 41(5):266-271. PubMed ID: 29705786
[TBL] [Abstract][Full Text] [Related]
26. Infigratinib in patients with advanced cholangiocarcinoma with
Makawita S; K Abou-Alfa G; Roychowdhury S; Sadeghi S; Borbath I; Goyal L; Cohn A; Lamarca A; Oh DY; Macarulla T; T Shroff R; Howland M; Li A; Cho T; Pande A; Javle M
Future Oncol; 2020 Oct; 16(30):2375-2384. PubMed ID: 32580579
[TBL] [Abstract][Full Text] [Related]
27. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
Rizzo A; Ricci AD; Brandi G
Cancer Treat Res Commun; 2021; 27():100356. PubMed ID: 33799004
[TBL] [Abstract][Full Text] [Related]
28. IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications.
Borger DR; Zhu AX
Expert Rev Anticancer Ther; 2012 May; 12(5):543-6. PubMed ID: 22594888
[No Abstract] [Full Text] [Related]
29. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with
Bekaii-Saab TS; Valle JW; Van Cutsem E; Rimassa L; Furuse J; Ioka T; Melisi D; Macarulla T; Bridgewater J; Wasan H; Borad MJ; Abou-Alfa GK; Jiang P; Lihou CF; Zhen H; Asatiani E; Féliz L; Vogel A
Future Oncol; 2020 Oct; 16(30):2385-2399. PubMed ID: 32677452
[TBL] [Abstract][Full Text] [Related]
30. Cholangiocarcinoma: investigations into pathway-targeted therapies.
Ntanasis-Stathopoulos I; Tsilimigras DI; Gavriatopoulou M; Schizas D; Pawlik TM
Expert Rev Anticancer Ther; 2020 Sep; 20(9):765-773. PubMed ID: 32757962
[TBL] [Abstract][Full Text] [Related]
31. Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.
Brown ZJ; Ruff SM; Pawlik TM
Expert Rev Anticancer Ther; 2023 Mar; 23(3):257-264. PubMed ID: 36744395
[TBL] [Abstract][Full Text] [Related]
32. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM
J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382
[TBL] [Abstract][Full Text] [Related]
33. [Medical management of cholangiocarcinomas in 2015].
Marret G; Neuzillet C; Rousseau B; Tournigand C
Bull Cancer; 2016 Apr; 103(4):389-99. PubMed ID: 26922666
[TBL] [Abstract][Full Text] [Related]
34. Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma.
Jensen LH; Jakobsen A
Expert Rev Anticancer Ther; 2011 Apr; 11(4):589-600. PubMed ID: 21504326
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
36. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
Borad MJ; Champion MD; Egan JB; Liang WS; Fonseca R; Bryce AH; McCullough AE; Barrett MT; Hunt K; Patel MD; Young SW; Collins JM; Silva AC; Condjella RM; Block M; McWilliams RR; Lazaridis KN; Klee EW; Bible KC; Harris P; Oliver GR; Bhavsar JD; Nair AA; Middha S; Asmann Y; Kocher JP; Schahl K; Kipp BR; Barr Fritcher EG; Baker A; Aldrich J; Kurdoglu A; Izatt T; Christoforides A; Cherni I; Nasser S; Reiman R; Phillips L; McDonald J; Adkins J; Mastrian SD; Placek P; Watanabe AT; Lobello J; Han H; Von Hoff D; Craig DW; Stewart AK; Carpten JD
PLoS Genet; 2014 Feb; 10(2):e1004135. PubMed ID: 24550739
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future.
Blair AB; Murphy A
Curr Probl Cancer; 2018; 42(1):49-58. PubMed ID: 29501212
[TBL] [Abstract][Full Text] [Related]
38. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi M; Bartholin L; Neuzillet C
World J Gastroenterol; 2018 May; 24(20):2137-2151. PubMed ID: 29853732
[TBL] [Abstract][Full Text] [Related]
39. Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets.
Tariq NU; Vogel A; McNamara MG; Valle JW
Oncol Res Treat; 2018; 41(5):298-304. PubMed ID: 29705791
[TBL] [Abstract][Full Text] [Related]
40. Microsatellite Instability-high Intrahepatic Cholangiocarcinoma with Portal Vein Tumor Thrombosis Successfully Treated with Pembrolizumab.
Naganuma A; Sakuda T; Murakami T; Aihara K; Watanuki Y; Suzuki Y; Shibasaki E; Masuda T; Uehara S; Yasuoka H; Hoshino T; Kudo T; Ishihara H; Ogawa T; Kitamoto Y; Ogawa A
Intern Med; 2020 Sep; 59(18):2261-2267. PubMed ID: 32536644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
